Suchergebnisse - William G. Wierda

Treffer weiter einschränken
  1. 1
    Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL

    Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL von Philip A. Thompson, William G. Wierda

    Veröffentlicht 2015
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  2. 2
    Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies

    Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies von Hussein A. Abbas, William G. Wierda

    Veröffentlicht 2021
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  3. 3
    AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistance

    AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistance von Kumudha Balakrishnan, Jan A. Burger, William G. Wierda, Varsha Gandhi

    Veröffentlicht 2008
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  4. 4
    CXCR4 is a prognostic marker in acute myelogenous leukemia

    CXCR4 is a prognostic marker in acute myelogenous leukemia von Anke Spoo, Michael Lübbert, William G. Wierda, Jan A. Burger

    Veröffentlicht 2006
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells

    Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells von Kumudha Balakrishnan, William G. Wierda, Michael J. Keating, Varsha Gandhi

    Veröffentlicht 2008
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  6. 6
    Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells

    Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells von Lisa S. Chen, Sanjeev Redkar, David J. Bearss, William G. Wierda, Varsha Gandhi

    Veröffentlicht 2009
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia

    Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia von Rong Chen, Lei Guo, Yuling Chen, Yingjun Jiang, William G. Wierda, William Plunkett

    Veröffentlicht 2010
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

    Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study von William G. Wierda, Swaminathan P. Iyer, Geoffrey Chan, Ira Gupta, Steen Lisby, Anders Österborg

    Veröffentlicht 2011
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  9. 9
    Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

    Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells von Claudia P. Miller, Sharmistha Rudra, Michael J. Keating, William G. Wierda, Michael A. Palladino, Joya Chandra

    Veröffentlicht 2009
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells

    Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells von Viralkumar Patel, Kumudha Balakrishnan, Елена Бибикова, Mary Ayres, Michael J. Keating, William G. Wierda, Varsha Gandhi

    Veröffentlicht 2016
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  11. 11
    Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells

    Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells von Kumudha Balakrishnan, Jan A. Burger, Maite P. Quiroga, Marina Henneberg, Mary Ayres, William G. Wierda, Varsha Gandhi

    Veröffentlicht 2010
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  12. 12
    Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia

    Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia von Deepa Sampath, Chaomei Liu, Karthik Vasan, Melanie Sulda, Vinay K. Puduvalli, William G. Wierda, Michael J. Keating

    Veröffentlicht 2011
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  13. 13
    Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins

    Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins von George F. Widhopf, Laura Z. Rassenti, Traci L. Toy, John G. Gribben, William G. Wierda, Thomas J. Kipps

    Veröffentlicht 2004
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  14. 14
    High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation

    High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation von Jan A. Burger, Maite P. Quiroga, Elena Hartmann, Andrea Bürkle, William G. Wierda, Michael J. Keating, Andreas Rosenwald

    Veröffentlicht 2008
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

    Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia von Fabiola Cervantes-Gomez, Betty Lamothe, Jennifer A. Woyach, William G. Wierda, Michael J. Keating, Kumudha Balakrishnan, Varsha Gandhi

    Veröffentlicht 2015
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  16. 16
    The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

    The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization von Julia Hoellenriegel, Dirk Zboralski, Christian Maasch, Nathalie Y. Rosin, William G. Wierda, Michael J. Keating, Anna Kruschinski, Jan A. Burger

    Veröffentlicht 2013
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  17. 17
    Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

    Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma von Yi Zhou, Guilin Tang, L. Jeffrey Medeiros, Timothy J. McDonnell, Michael J. Keating, William G. Wierda, Sa A. Wang

    Veröffentlicht 2011
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

    Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia von Rong Chen, William G. Wierda, Sherri Chubb, Rachael E. Hawtin, Judith A. Fox, Michael J. Keating, Varsha Gandhi, William Plunkett

    Veröffentlicht 2009
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells

    Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells von Hima V. Vangapandu, Brandon Alston, Joshua Morse, Mary Ayres, William G. Wierda, Michael J. Keating, Joseph R. Marszalek, Varsha Gandhi

    Veröffentlicht 2018
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia

    Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia von Paolo Strati, William G. Wierda, Jan A. Burger, Alessandra Ferrajoli, Constantine S. Tam, Susan Lerner, Michael J. Keating, Susan O’Brien

    Veröffentlicht 2013
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: